دورية أكاديمية
Antitumoral effects of γCdcPLI, a PLA 2 inhibitor from Crotalus durissus collilineatus via PI3K/Akt pathway on MDA-MB-231 breast cancer cell.
العنوان: | Antitumoral effects of γCdcPLI, a PLA |
---|---|
المؤلفون: | Gimenes SNC; Federal University of Uberlandia, Uberlandia, MG, Brazil., Lopes DS; Federal University of Uberlandia, Uberlandia, MG, Brazil., Alves PT; Federal University of Uberlandia, Uberlandia, MG, Brazil., Azevedo FVPV; Federal University of Uberlandia, Uberlandia, MG, Brazil., Vecchi L; Federal University of Uberlandia, Uberlandia, MG, Brazil., Goulart LR; Federal University of Uberlandia, Uberlandia, MG, Brazil., Rodrigues TCS; Federal University of Uberlandia, Uberlandia, MG, Brazil., Santos ALQ; Federal University of Uberlandia, Uberlandia, MG, Brazil., Brites VLC; Federal University of Uberlandia, Uberlandia, MG, Brazil., Teixeira TL; Federal University of Uberlandia, Uberlandia, MG, Brazil., da Silva CV; Federal University of Uberlandia, Uberlandia, MG, Brazil., Dias MH; Butantan Institute, São Paulo, Brazil., Teixeira SC; Federal University of Uberlandia, Uberlandia, MG, Brazil., Rodrigues RS; Federal University of Uberlandia, Uberlandia, MG, Brazil., Yoneyama KAG; Federal University of Uberlandia, Uberlandia, MG, Brazil., Oliveira RA; Federal University of Uberlandia, Uberlandia, MG, Brazil., Rodrigues VM; Federal University of Uberlandia, Uberlandia, MG, Brazil. veridiana@ufu.br. |
المصدر: | Scientific reports [Sci Rep] 2017 Aug 01; Vol. 7 (1), pp. 7077. Date of Electronic Publication: 2017 Aug 01. |
نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
اللغة: | English |
بيانات الدورية: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: London : Nature Publishing Group, copyright 2011- |
مواضيع طبية MeSH: | Breast Neoplasms*, Antineoplastic Agents/*pharmacology , Lipoproteins/*pharmacology , Oncogene Protein v-akt/*metabolism , Phosphatidylinositol 3-Kinase/*metabolism , Phospholipase A2 Inhibitors/*pharmacology, Antineoplastic Agents/isolation & purification ; Cell Adhesion/drug effects ; Cell Line, Tumor ; Cell Movement/drug effects ; Cell Survival/drug effects ; Crotalid Venoms/chemistry ; Endothelial Cells/drug effects ; Humans ; Lipoproteins/isolation & purification ; Models, Biological ; Neovascularization, Pathologic ; Phospholipase A2 Inhibitors/isolation & purification |
مستخلص: | Phospholipases A |
References: | PLoS One. 2010 Apr 12;5(4):e10124. (PMID: 20405031) J Biol Chem. 2001 Jan 12;276(2):1564-9. (PMID: 11036077) Toxicol Appl Pharmacol. 2014 Oct 1;280(1):10-20. (PMID: 25094029) Neuro Oncol. 2010 Oct;12(10):1014-23. (PMID: 20639215) Nature. 1992 Jul 2;358(6381):80-3. (PMID: 1614537) Am J Pathol. 2008 Mar;172(3):809-17. (PMID: 18276787) FASEB J. 2017 Mar;31(3):1107-1119. (PMID: 27974593) Nat Protoc. 2011 Dec 22;7(1):89-104. (PMID: 22193302) Interv Med Appl Sci. 2014 Dec;6(4):139-46. (PMID: 25598986) Biochimie. 2014 Dec;107 Pt A:114-23. (PMID: 25286228) Breast Cancer Res. 2009;11(1):R1. (PMID: 19123925) Biochem Biophys Res Commun. 2014 Feb 28;445(1):230-5. (PMID: 24508801) J Clin Invest. 1997 Feb 1;99(3):373-6. (PMID: 9022067) Breast Cancer Res Treat. 2013 Aug;140(3):587-601. (PMID: 23912956) Dig Dis Sci. 1998 Oct;43(10):2261-6. (PMID: 9790463) Ann Intern Med. 2007 Mar 6;146(5):376-89. (PMID: 17339623) Methods Mol Biol. 2016;1430:205-19. (PMID: 27172956) Cancer Res. 1997 Mar 1;57(5):963-9. (PMID: 9041202) Cytokine Growth Factor Rev. 2005 Feb;16(1):77-89. (PMID: 15733833) Methods Cell Biol. 2011;103:55-98. (PMID: 21722800) Methods. 2001 Dec;25(4):402-8. (PMID: 11846609) Breast Cancer Res Treat. 2008 Sep;111(1):27-44. (PMID: 17922188) Biochem J. 2011 Dec 1;440(2):251-62. (PMID: 21834793) BMC Cancer. 2013 Nov 14;13:545. (PMID: 24229379) Br J Cancer. 1994 Jun;69(6):1166-70. (PMID: 8198986) Breast Cancer Res Treat. 2010 Nov;124(1):63-77. (PMID: 20052536) Cell. 2000 Jan 7;100(1):57-70. (PMID: 10647931) Bioorg Med Chem. 2016 Jul 1;24(13):3029-34. (PMID: 27234891) Int J Cancer. 2015 Nov 15;137(10 ):2424-31. (PMID: 25974157) J Biol Chem. 2013 Feb 1;288(5):3289-304. (PMID: 23235151) Breast Cancer Res Treat. 2008 Sep;111(2):209-18. (PMID: 17932742) Nat Rev Cancer. 2010 Mar;10(3):181-93. (PMID: 20168319) Exp Cell Res. 2003 Feb 15;283(2):247-55. (PMID: 12581744) Phytother Res. 2015 Jul;29(7):969-77. (PMID: 25907962) Chem Biol Interact. 2014 Mar 5;210:51-63. (PMID: 24365254) Toxicol Appl Pharmacol. 2013 Oct 1;272(1):37-48. (PMID: 23747687) BMC Complement Altern Med. 2016 Feb 27;16:86. (PMID: 26922065) Cancer. 1993 May 15;71(10 ):3058-64. (PMID: 8490834) Oncogene. 2004 Oct 21;23 (49):8146-53. (PMID: 15361831) J Biol Chem. 2001 Mar 9;276(10):7320-6. (PMID: 11058599) Toxicon. 2014 Aug;86:16-27. (PMID: 24814013) Cell. 2001 Feb 23;104(4):487-501. (PMID: 11239407) Mol Carcinog. 2013 Nov;52 Suppl 1:E52-9. (PMID: 23143756) Stem Cells. 2016 Sep;34(9):2290-305. (PMID: 27301070) Oncogene. 2007 May 14;26(22):3279-90. (PMID: 17496922) Cell. 1989 Jun 30;57(7):1083-93. (PMID: 2525423) Breast Cancer Res. 2008;10 Suppl 1:S2. (PMID: 19091006) J Biol Chem. 2001 May 25;276(21):18075-81. (PMID: 11278548) Semin Cancer Biol. 2015 Dec;35:180-90. (PMID: 26192967) J Cancer Res Clin Oncol. 2011 Nov;137(11):1587-94. (PMID: 21904903) Cell. 2002 Sep 20;110(6):673-87. (PMID: 12297042) Cytokine Growth Factor Rev. 2005 Apr;16(2):159-78. (PMID: 15863032) Toxicon. 2014 Apr;81:58-66. (PMID: 24513130) Cancer Res. 1998 Sep 15;58(18):4023-37. (PMID: 9751603) J Biol Chem. 1992 Jun 5;267(16):10931-4. (PMID: 1375931) Pharmacol Res. 2015 Mar;93:1-10. (PMID: 25533812) Int J Biochem Cell Biol. 2013 May;45(5):1012-5. (PMID: 23428797) Head Neck. 2016 Apr;38 Suppl 1:E360-71. (PMID: 25580586) J Clin Invest. 2007 Nov;117(11):3155-63. (PMID: 17975657) Cytokine Growth Factor Rev. 2005 Apr;16(2):179-86. (PMID: 15863033) Cell. 1996 Dec 27;87(7):1153-5. (PMID: 8980221) Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8. (PMID: 12516034) Science. 1989 Apr 14;244(4901):217-21. (PMID: 2649981) Oncogene. 2007 Feb 26;26(9):1338-45. (PMID: 17322919) Mol Cancer. 2013 Sep 27;12(1):111. (PMID: 24070020) Toxicol Appl Pharmacol. 2014 Sep 15;279(3):311-21. (PMID: 25026504) Cardiovasc Res. 1996 Oct;32(4):687-98. (PMID: 8915187) Cancer Res. 2002 Jan 1;62(1):63-6. (PMID: 11782360) Toxicol Pathol. 2007 Jun;35(4):495-516. (PMID: 17562483) Anal Biochem. 1976 May 7;72:248-54. (PMID: 942051) CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29. (PMID: 24399786) Front Oncol. 2015 Apr 27;5:89. (PMID: 25964882) Science. 1990 Aug 24;249(4971):912-5. (PMID: 2144057) Prostate. 2015 Sep;75(13):1394-402. (PMID: 26073992) J Cell Biol. 2002 Jul 22;158(2):235-46. (PMID: 12135983) Bioorg Chem. 2016 Jun;66:124-31. (PMID: 27149364) Nat Rev Mol Cell Biol. 2004 Oct;5(10):816-26. (PMID: 15459662) Int J Dev Biol. 2011;55(4-5):447-53. (PMID: 21858770) FASEB J. 2015 Sep;29(9):4036-45. (PMID: 26085132) Biochem Pharmacol. 2007 Oct 1;74(7):949-59. (PMID: 17531957) Int J Cancer. 2005 Nov 10;117(3):409-17. (PMID: 15906362) Mutat Res. 1999 Dec 17;431(2):199-209. (PMID: 10635987) Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74. (PMID: 11553815) Breast Dis. 2010;32(1-2):35-48. (PMID: 21778573) Genome Biol. 2001;2(3):REVIEWS3005. (PMID: 11276432) Nat Med. 1997 Aug;3(8):917-21. (PMID: 9256286) Vasc Health Risk Manag. 2006;2(3):213-9. (PMID: 17326328) |
المشرفين على المادة: | 0 (Antineoplastic Agents) 0 (Crotalid Venoms) 0 (Lipoproteins) 0 (Phospholipase A2 Inhibitors) EC 2.7.1.137 (Phosphatidylinositol 3-Kinase) EC 2.7.11.1 (Oncogene Protein v-akt) |
تواريخ الأحداث: | Date Created: 20170803 Date Completed: 20190212 Latest Revision: 20190215 |
رمز التحديث: | 20240628 |
مُعرف محوري في PubMed: | PMC5539153 |
DOI: | 10.1038/s41598-017-07082-2 |
PMID: | 28765552 |
قاعدة البيانات: | MEDLINE |
تدمد: | 2045-2322 |
---|---|
DOI: | 10.1038/s41598-017-07082-2 |